Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease

Bibliography

• Gearry RB, Richardson A, Frampton CMA, High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study Inflamm Bowel Dis. 2006;12:936-43
   Google Scholar
• Australian Institute of Health and Welfare. Australian Hospital Statistics. 1993-95, 1995-96, 1996-97, 1999-00, 2000-01, 2002-03. Australian Government, Canberra
   Google Scholar
• Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10:445-56
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DP, Barrett JC, Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25
   PubMed Web of Science ®Google Scholar
• Anderson CA, Boucher G, Lees CW, Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43(3):246-52
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
   PubMed Web of Science ®Google Scholar
• Hassard PV, Vasiliauskas EA, Kam LY, Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 2000;6:16-20
   PubMed Web of Science ®Google Scholar
• Alfakih K, Lawrance RA, Maqbool A, The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease. Eur Heart J 2005;26:584-9
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A, Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Czegledi Z, Szamosi T, Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009;15:3504-10
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol 2007;22:1671-7
   PubMed Web of Science ®Google Scholar
• Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009;24:1252-7
   PubMed Web of Science ®Google Scholar
• Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008;14:2544-9
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33
   PubMed Web of Science ®Google Scholar
• Alfakih K, Brown B, Lawrance RA, Effect of a common X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization. Atherosclerosis 2007;195:e32-8
   PubMedGoogle Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87
   PubMed Web of Science ®Google Scholar
• Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev 2003;2:703-16
   Google Scholar
• Yednock TA, Cannon C, Fritz LC, Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-6
   PubMed Web of Science ®Google Scholar
• Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002;22:146-67
   PubMed Web of Science ®Google Scholar
• Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14
   PubMed Web of Science ®Google Scholar
• Arihiro S, Ohtani H, Suzuki M, Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int 2002;52:367-74
   PubMed Web of Science ®Google Scholar
• Briskin M, Winsor-Hines D, Shyjan A, Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78
   PubMed Web of Science ®Google Scholar
• Rott LS, Briskin MJ, Andrew DP, A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J Immunol 1996;156:3727-36
   PubMed Web of Science ®Google Scholar
• Picarella D, Hurlbut P, Rottman J, Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997;158:2099-106
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ, Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111:1373-80
   PubMed Web of Science ®Google Scholar
• Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009;9:836-50
   PubMed Web of Science ®Google Scholar
• Zaballos A, Gutierrez J, Varona R, Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 1999;162:5671-5
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Prehn J, Moreno ST, CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001;121:246-54
   PubMed Web of Science ®Google Scholar
• Saruta M, Yu QT, Avanesyan A, Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol 2007;178:3293-300
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23
   PubMed Web of Science ®Google Scholar
• Tubridy N, Behan PO, Capildeo R, The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999;53:466-72
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
   PubMed Web of Science ®Google Scholar
• Su C, Lichtenstein GR, Krok K, A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8
   PubMed Web of Science ®Google Scholar
• Verbeeck J, Van Assche G, Ryding J, JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008;57:1393-7
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Vernier-Massouille G, Viget N, Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-alpha4 integrin therapy? Gut 2008;57:1633-4; author reply 4
   PubMed Web of Science ®Google Scholar
• Clifford DB. Natalizumab and PML: a risky business? Gut 2008;57:1347-9
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, Natalizumab for active Crohn's disease. N Engl J Med 2003;34:24-32
   Web of Science ®Google Scholar
• Gordon FH, Lai CW, Hamilton MI, A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
   PubMed Web of Science ®Google Scholar
• Higgins JM, Mandlebrot DA, Shaw SK, Direct and regulated interaction of integrin alphaEbeta7 with E-cadherin. J Cell Biol 1998;140:197-210
   PubMed Web of Science ®Google Scholar
• Cepek KL, Parker CM, Madara JL. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993;150:3459-70
   PubMed Web of Science ®Google Scholar
• Elewaut D, De Keyser F, Cuvelier C, Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1998;33:743-8
   PubMed Web of Science ®Google Scholar
• Demetter P, De Vos M, Van Damme N, Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol 2000;114:364-70
   PubMed Web of Science ®Google Scholar
• Ludviksson BR, Strober W, Nishikomori R, Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice. J Immunol 1999;162:4975-82
   PubMed Web of Science ®Google Scholar
• Stefanich EG, Danilenko DM, Wang H, A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011;162:1855-70
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Campbell JJ, Haraldsen G, Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000;192:761-8
   PubMed Web of Science ®Google Scholar
• Zabel BA, Agace WW, Campbell JJ, Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999;190:1241-56
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Prehn J, Nelson V, The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000;165:5069-76
   PubMed Web of Science ®Google Scholar
• Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010;13:472-781
   PubMed Web of Science ®Google Scholar
• Walters MJ, Wang Y, Lai N, Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010;335:61-9
   PubMed Web of Science ®Google Scholar
• Keshav S, Johnson D, Bekker P. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate-to-severe Crohn's disease. Gastroenterology 2009;136:A65
   PubMed Web of Science ®Google Scholar
• Keshav S, Vana´sek T, Niv Y, PROTECT-1 study of intestine-specific chemokine receptor antagonist CCX282-B (TRAFICET-EN) in Crohn's disease. Gut 2009;58:A468
   PubMed Web of Science ®Google Scholar